Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) critical ailment formulations, is excited to announce the appointment of world renowned Cannabis Cultivator Bret Bogue as Director of Horticulture for the company. Mr. Bogue is a valuable addition to the company, with decades of experience growing cannabis for medical purposes. Mr. Bogue will play a key role in the development and maintenance of all horticulture operations for the company while developing specific strains for mass production for the company’s growing standards and critical ailment formulations developed by the company. Mr. Bogue will be a part of the lead development team for plants and strains to be used to develop these medical cannabis formulations and products for Cannabis Science. Being a critical cancer patient himself, Mr. Bogue was diagnosed with a very rare form of melanoma in 1995. Mr. Bogue stated, "I became very ill and was looking for an alternative medication for my illness, so I realized then that I needed to create Apothecary™ Genetics to provide an alternative treatment solution in the early 90s. Through my world travels, I have been able to find ‘land race strains’ and breed them with hybrids to create World Class medical cannabis.” Bret and Apothecary went on to become the first American-based seed company to win the coveted Cannabis Cup in Amsterdam in 2007, and has won many other international and national awards for his medical cannabis developments. Having over 20 years of experience creating unique medical strains of cannabis, such as Grape Ape aka GDP, Kaia Kush, Sour Grapes, Old School Jams, and Goo, just to name a few, has put Bret and Apothecary Genetics on the world map as one of the top leaders in medical cannabis development. Mr. Bogue concludes with, “ I was able to cure my melanoma by using medical cannabis in combination with standard radiation treatment. I am the living proof that medical cannabis kills cancer cells.” As well, Bret is embarking on some exciting new projects such as a documentary with television giant A&E. Two pilots have already been filmed and sent to New York for review and approvals. The documentary will show real patients who are having real, positive results with medical cannabis. These patients include seniors from a senior citizens’ community in California. Viewers will see the reality of the medication’s benefits, as well as the emotions that come into play when someone is chronically ill. About Cannabis Science, Inc. Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. Forward Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S.
Top 10 Most Recent News Articles
Heafner Takes Helm at HGTC Amid Strategic Shifts
A New Era for HGTC with Dr. Heafner at the Wheel Out of the frying pan and into the fire—Dr. Lori Heafner is stepping up to lead Horry-Georgetown Technical College (HGTC) with a clean slate and a hefty load of responsibility come January 2027. After enduring an intense national search by the Area Commission, she beat out tough competition to earn the role. It's not just...
Continue Reading
AI Agents Challenge Product Governance Models
AI's Increasing Role: A Double-Edged Sword for Leaders Hey, the tech overlords remind us once again—the future doesn't wait for anyone to catch up before it bulldozes forward. Info-Tech Research Group has sounded the alarm on AI agents muscling their way into product decisions without any clear nod from the human corner office. Blurring Lines of Accountability The...
Continue Reading
Crimson Coward's Cheez Nugs Shake Up Fast-Casual Scene
New Kid on the Block: Cheez Nugs Buckle up folks, Crimson Coward is at it again. They're rolling out something they claim will blow your taste buds straight out of the water: Cheez Nugs. Dropping nationwide on September 18, 2026, these aren't your run-of-the-mill cheese bites. We're talking 100% whole-milk mozzarella, a golden herb-seasoned crust, and a mouthful of creamy...
Continue Reading
Chattanooga: A New Epicenter for Quantum Computing
Quantum Leap: Chattanooga's Bold Move So Chattanooga’s making waves again, folks. EPB just unveiled its new big shot, the IonQ Forte Enterprise quantum computer. That's right, they’ve slapped a commercial quantum computer and a networking hub together, right here in this Tennessee city. Is this a tech haven or what? Not to mention, it’s the first in America. A New...
Continue Reading
Bellissima Bags Allure Award for Curly Hair Tool
Award-Winning Tool Headlines 2026 Beauty Scene There's a shake-up in the world of hair tools, folks. Bellissima's Diffon Supreme has snagged a 2026 Allure Best of Beauty Award for its prowess in taming the curly, wavy, and coily strands we all crave to manage. Performance Meets Innovation in Bellissima's Latest Let's not beat around the bush. The Diffon Supreme's trump...
Continue Reading
DAHON's Tech: Crafting Folders That Ride Like Road Bikes
The Folding Bike Revolution: More Than Just a Fad You've seen them zipping around—those compact, folding bikes. They're not just for urban commuters looking to save space. Oh no, this is a full-blown cycling revolution we're talking about. DAHON, a name that's been rolling since 1982, has been riding these waves and making strides that others can only dream of. While...
Continue Reading
FOSSI Opens 2027 Applications for Future STEM Leaders
Paving Pathways in the Chemical Industry There's something brewing that's got me eyeing the future with cautious optimism, and it doesn't involve hedge funds or earnings reports. It's the Future of STEM Scholars Initiative (FOSSI) playing its cards just right, planting seeds for tomorrow's innovators. This puppy opened the gates for 2027 applications, and for young brains...
Continue Reading
AI Ambassadors Rethink Arbitration's Future
Navigating the AI Terrain in Arbitration It's 2026 and artificial intelligence isn't just a buzzword anymore; it's reshaping every corner of how disputes get resolved. The American Arbitration Association (AAA) has jumped into the mix, launching an AI Ambassador program to tackle a wave of AI-induced challenges. These aren't just academic exercises—this is a hard-nosed...
Continue Reading
Digital Wine Atlas Maps 4.3 Million Vineyards Globally
Revolutionizing Viticulture with Data In today's wild world, climate change isn't just shifting weather patterns—it's upending the age-old map of wine-making regions. We've got a new player on the field: the World Winery Map. It's digital, massive, and it’s shaking things up for winemakers and grape enthusiasts alike. This platform covers a staggering 4.3 million...
Continue Reading
Arizona Voters Demand Clear Plans for 2026 Election
A Shift in Voter Expectations: Clear Actions Needed Arizona voters have spoken, and they aren't looking for the same old political song and dance anymore. They crave something meatier—action, not just words. Heading into the 2026 general election, folks in the Grand Canyon State are demanding concrete solutions and straightforward answers from those who seek to lead...
Continue ReadingTop 5 Most Recently Viewed Articles
Northfield Capital Secures $2.1M Through Private Placement
Northfield Capital Completes Successful Equity Offering Northfield Capital Corporation (TSX-V: NFD.A) has recently wrapped up a significant non-brokered private placement, successfully raising $2,146,000 through the issuance of 107,300 units. Each unit is priced at $20.00 and comprises one class A restricted voting share and a share purchase warrant. Investors will be...
Continue Reading
Transforming Mortgages: VantageScore 4.0 Reshapes Home Buying
VantageScore 4.0 Implementation Marks a New Era in Mortgages The Federal Housing Finance Agency (FHFA) is making a bold move by allowing the use of VantageScore 4.0 for mortgages sold to significant players in the housing market. This pivotal decision brings much-needed competition to the credit scoring landscape, which has remained largely unchanged for decades. By...
Continue Reading
Exploring AYVAKIT's Promise for Systemic Mastocytosis Patients
Blueprint Medicines Highlights AYVAKIT Efficacy for Systemic Mastocytosis Blueprint Medicines Corporation has recently unveiled data demonstrating the sustained clinical efficacy and safety profile of AYVAKIT (avapritinib) for the treatment of systemic mastocytosis (SM). The company continues to underscoring its commitment to improving patient care through a series of...
Continue Reading
Josh Allen Rookie Card Sells for Record $1.7M
Million-Dollar Card: A Trophy for Investors Think back to a time when shelling out a few bucks for trading cards was child's play. Fast forward to today, and we have a Josh Allen 1/1 rookie card going under the hammer for a jaw-dropping $1.7 million. Yeah, that's right—a sports card rivaling pieces of modern art in valuation. Who'd have guessed it? This figure not only...
Continue Reading
Lessons from a Failed Launch: Why Solana Developers Can't Ignore Infrastructure Planning
The launch was supposed to be perfect. Jasmine and her team had spent six months building a Solana-based NFT marketplace. She'd even set a launch date and invited 1,000 early access users. Then launch day arrived, and within the first hour, her marketplace crashed. As she picked through the wreckage of her launch, she realized the fatal mistake: she'd built an incredible...
Continue Reading